Industry

FDA approves Vabysmo label update for macular edema due to RVO

Healio Optometry1d ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.The FDA approved an updated label for Vabysmo for the treatment of macular edema following retinal vein occlusion beyond 6 months, according to a Genentech press release.Vabysmo (faricimab-svoa) is a bispecific antibody that inhibits angiopoietin-1 and VEGF-A. It is also approved for the treatment of neovascular age-related macular degeneration and diabetic macular edema.It was approved for macular edema due to retinal vein occlusion (RVO) in 2023, and the label update allows patients to continue using it

Read full article on Healio Optometry

AI Summary

Quick Take

The FDA has approved a label update for Vabysmo (faricimab-svoa) that allows for the continued treatment of macular edema following retinal vein occlusion (RVO) beyond six months. This regulatory expansion enables long-term use of the bispecific antibody, which targets both Ang-2 and VEGF-A, for patients with chronic RVO-related edema.

Why It Matters

While Vabysmo received its initial RVO approval in 2023, the label update addresses the clinical reality that many RVO patients require therapy well beyond the first half-year to maintain visual gains and control edema. By securing a label for extended use, Genentech provides retina specialists with the formal framework to utilize dual-pathway inhibition for long-term disease management. This is particularly relevant for reducing treatment burden, as the Ang-2 inhibition component is designed to improve vascular stability more effectively than VEGF monotherapy alone.

Key Details

The FDA label update specifically covers the treatment of macular edema following retinal vein occlusion (RVO) beyond the initial 6-month period.
Vabysmo (faricimab-svoa) is the first bispecific antibody approved for the eye, inhibiting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).
The medication is also FDA-approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
The update follows the drug's initial RVO approval granted in 2023.

Practice Implications

Retina specialists can now transition RVO patients to long-term maintenance therapy with Vabysmo with full regulatory support. This allows for more flexible dosing strategies beyond the initial six months for patients who may benefit from the dual-pathway mechanism to achieve extended treatment intervals.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

What's Next

As this is a developing story, further details regarding the specific clinical data supporting the long-term label update are expected. Clinicians should look for updated prescribing information to guide dosing intervals for RVO patients entering the maintenance phase of treatment.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.